A NEW FAMILY OF COMPOUNDS HAVING ANTI-INFLAMMATORY AND ANTI-VIRAL ACTIVITY AND COMPOSITIONS OF THESE, ALONE AND IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS, FOR INHIBITING, PREVENTING OR ELIMINATING VIRAL REPLICATION AND METHODS OF USING SAME

Abstract: A new family of compounds having anti-inflammatory, anti-viral, and broncho-dilating activity having linear formula (I) and cyclic formula (II), and compositions of these, which alone, and in combination with reverse transcriptase inhibitors thereby resulting in an additive or synergistic effect, are useful in inhibiting or suppressing viruses including those exhibiting retroviral replication, or eliminating viruses including a retrovirus such as HIV in a human cell population and methods of using these compositions, compounds, and salts thereof.

Description: A NEW FAMILY OF COMPOUNDS HAVING ANTI-INFLAMMATORY AND ANΗ- VIRAL ACTTV- ITY AND COMPOSITIONS OF THESE, ALONE AND IN COMBINATION WITH REVERSE TRAN¬ SCRIPTASE INHIBITORS. FOR INHIBITING, PREVENTING OR ELIMINATING VIRAL REPLICA¬ TION AND METHODS OF USING SAME BACKGROUND OF THE INVENTION 1. FIELD OF THE INVENTION The present invention relates to a new family of compounds having anti-inflammatory, and anti-viral, and broncho-dilating activity which, additionally, in combination with a reverse transcriptase inhibitor results in an additive or synergistic effect which is useful in inhibiting or suppressing retroviral replication or eliminating a retrovirus in a human cell population. 2. DESCRIPTION OF RELATED ART The expression "Acquired Immuno-Deficiency Syndrome" (AIDS) was first used in 1981 to describe a state of cellular immune deficiency in homosexuals, characterized by the appearance of opportunistic infections and Kaposi's Sarcoma evolving very aggressively [CDC (Center for Disease Control) , MMWR, 1981; 30: 305- 308.DC]. In 1983, a retrovirus since called HIV (Human Immunodeficiency Virus) was isolated among AIDS patients (Barre-Sinoussi F, et al., Science. 1983; 220: 868-871) . Over the past several years, researchers and clinicians have gained considerable experience in studying and caring for individuals infected with HIV throughout the often prolonged course of HIV disease and AIDS. On the basis of this experience, it has become clear that the pathogenic mechanisms underlying HIV infection and disease are not unidimensional, but rather are extremely complex (Fauci AS, Science. 1988; 239: 617) . Any attempt to design cytostatic activity, which gives them a broad therapeutic index when used for their antiviral effect in an infected cell population. Additionally, these compounds have been found to be useful in treating asthma and have a therapeutic potential as anti-inflammatory agents and broncho-dilating agents for treating a range of diseases which includes arthritis and asthma-like diseases. R.M. McMillan and E.R.H. Walker in "Designing Therapeutically Effective 5- Lipogenase Inhibitors" Elsevier Science Publishers Ltd., TIPS, Vol. 13, (August, 1992) pp. 323-330 disclose that there are three classes of 5-lipoxygenase inhibitors: "redox" inhibitors, "non redox" inhibitors, and "iron ligand" inhibitors and that hydroxamate compounds are powerful iron ligand inhibitors. Although not being bound by theory, it is expected that by blocking the synthesis of leukotrienes known to be powerful broncho-constrictor agents, this new family of hydroxamate compounds has therapeutic potential both as an anti-inflammatory agent and as a broncho-dilating agent, specifically in a range of diseases which includes arthritis and asthma. It is to be noted that all references cited herein are expressly incorporated, in total, by reference thereto. -4- probability of drug resistant isolates. After entry of the HIV virus into cells and uncoating of the HIV particle, reverse transcription of the viral RNA genome into DNA replicas occurs. Among several forms of unintegrated viral DNA (now containing the long repeats [LTRs] , at both the 5' and the 3' ends), only the two-LTR linear forms can integrate into the host genome. Such a process appears strictly dependent upon cell activation/replication of T lymphocytes, although "resting" T cells are clearly susceptible to HIV infection. (Zack J.A, et al., Cell. 1990; 61: 213-222). Furthermore, part of the reverse transcription process also can occur in unactivated T cells, a process that results in the accumulation of incomplete DNA molecules, which may persist for several hours and remain capable of being integrated into the host genome if the cell undergoes sufficient activation (Zack J.A, et al. , Cell. 1990; 61: 213-222) . Therefore, infected "resting" CD4+T lymphocytes can be considered a transient viral reservoir in infected individuals (Bukrinsky M.I, et al. Science. 1991; 254: 423-427), and a high HIV burden has also been observed in lymphoid tissue as intracellular virus in latent form (Embretson J, et al., Nature. 1993; 362: 359- 362) . A new family of compounds has been found to be useful alone and in combination with reverse transcriptase inhibitors in inhibiting retroviral replication and eliminating retroviruses in human cell populations and in particular in HIV-infected resting human lymphocytes. Included in this family are the new compounds D-acetamido- N-hydroxy succinamic acid; D-acetamido-N-hydroxy succinimide; D-trifluoroacetamido-N-hydroxy succinamic acid; D-trifluoroacetamido-N-hydroxy succinimide; and salts thereof. Furthermore, these compounds have been found to have the advantage over other antiviral agents in that they have very little, if any, cytotoxic or Inter alia such a compound is selected from the group consisting of D-acetamido-N-hydroxy succinamic acid (DANHSA) , D-acetamido-N-hydroxy succinimide, D-trifluoro acetamido-N-hydroxy succinamic acid (DTFANHSA) , D-trifluoroacetamido-N-hydroxy succinimide ; and salts thereof. The invention relates also to a composition comprising a compound such as previously described, and one reverse transcriptase inhibitor (RT inhibitor) , acting a synergistic combination if this composition is comprised within a medicament. Preferably, the RT inhibitor is a dideoxynucleoside, in particular selected from the group consisting of AZT, ddC, ddA, ddG, ddl, ddT, 3TC and d4T. For example the dideoxynucleoside is ddl, AZT, ddC, or 3TC. In such a composition, the concentration of the compound as previously defined is possibly selected from the group consisting of the following concentration ranges : - from about 0,5 μM to about 20000 μM ; - from about 1 μM to about 10000 μM ; - from about 5 μM to about 5000 μM ; - from about 10 μM to about 1000 μM. In such a composition, the concentration of the RT inhibitor is possibly selected from the group consisting of the following concentration ranges : - from about 0,01 μM to about 200 μM ; - from about 0,1 μM to about 100 μM ; - from about 0,2 μM to about 10 μM. The invention relates also to a medicament comprising a compound or a composition, as previously defined. In such a medicament, its composition is eventually further selected so as to provide a plasma concentration selected from the group consisting of the following concentration ranges : -6- SUMMARY OF THE INVENTION The invention relates to a compound having the following linear or cyclic formulas: I (linear form) II (cyclic form) wherein R 1 is an alkyl group of from 1 to 4 carbon atoms optionally mono-, -di, or tri-substituted with halogen; each of R 2 , R 3 , and R 4 is hydrogen, or a straight or branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl radical containing 2 to 8 carbon atoms, an alkynyl radical containing 2 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a cycloalkenyl radical containing from 4 to 6 carbon atoms or a bicycloalkyl radical containing 7 to 11 carbon atoms, these radicals optionally being substituted by at least one substituent selected from halogen, hydroxyl, alkyloxy containing 1 to 4 carbon atoms, dialkyl amino, in which each alkyl contains 1 to 4 carbon atoms, phenyl alkyl in which the alkyl contains 1 to 4 carbon atoms, cyclo alkyl containing 3 to 6 carbon atoms, optionally substituted phenyl, cyano, carboxyl, or alkyloxy carbonyl in which the alkyl contains 1 to 4 carbon atoms; n is an integer from 0 to 6; and salts thereof. BRIEF DESCRIPTION OF THE FIGURES Figure 1 graphically depicts a study of the anti¬ viral activity of DANHSA on non-activated human PBMC infected with the HIV virus. (EFFECT OF DRUG TREATMENT ON HIV-1 p24 PRODUCTION IN INFECTED RESTING HUMAN LYMPHOCYTES) virus control -Δ — DANHSA lOμM DANHSA iooμM FIGURE: 1 DANHSA lOOOμM Figure 2 (a, b, c) each graphically depicts a study of the antiviral activity of DANHSA in combination with AZT on non-activated human PBMC infected with the HIV virus. (EFFECT OF DRUG TREATMENT ON HIV-1 p24 PRODUCTION IN INFECTED RESTING HUMAN LYMPHOCYTES) l OμM + AZT 4μM OμM FIGURE: 2a + AZT 4μM FIGURE: 2b -8- - from about 0,5 μM to about 20000 μM ; - from about 1 μM to about 10000 μM ; - from about 5 μM to about 5000 μM ; - from about 10 μM to about 1000 μM. This medicament further comprises if required a pharmaceutically acceptable carrier, or excipient, or vehicle, or combination thereof. The medicament previously defined is in particular for use in inhibiting the production or spread of a virus, or for limiting the spread of a virus, or for blocking the production of a virus. This virus is in particular selected from the group consisting of HSV Type 1, HSV Type 2, HBV, HCV, CMV and Epstein Barr. This virus is in particular a retrovirus, for example a retrovirus selected from the group consisting of HIV-1, HIV-2, HTLV-1, HTLV-2, and SIV. As an anti-retroviral medicament, it may further comprise another medicinal composition or compound intended for treatment of retroviral infections, selected from the group consisting of immunostimulants, immunomodulators, cytokines, IL-2, IL-12, and interferon molecules. A preferential but non exclusive use of a medicament as previously defined is the treatment of HIV infected and AIDS patients. l OOOμM + ddC 0.2μM OOOμlvi FIGURE: 3c Figure 4 (a, b, c) each graphically depicts a study of the antiviral activity of DANHSA in combination with ddl on non-activated human PBMC infected with the HIV virus. (EFFECT OF DRUG TREATMENT ON HIV-1 p24 PRODUCTION IN INFECTED RESTING HUMAN LYMPHOCYTES) μM+ddJ lOμM μM FIGURE: 4a ~~~ O — virus control lOOμM + ddllOμM lOOμM FIGURE: 4b -10- μM + AZT 4μM μM FIGURE: 2c Figure 3 (a, b, c) each graphically depicts a study of the antiviral activity of DANHSA in combination with ddC on non-activated human PBMC infected with the HIV virus. (EFFECT OF DRUG TREATMENT ON HIV-1 p24 PRODUCTION IN INFECTED RESTING HUMAN LYMPHOCYTES) l OμM + ddC 0.2μM OμM FIGURE: 3a M + ddC0.2μM M FIGURE: 3b -9- M + 3TC 5μM DANHSA lOOOμM FIGURE:5c Figure 6 graphically depicts a study of the anti- viral activity of DTFANHSA on non-activated human PBMC infected with the HIV-virus. (EFFECT OF DRUG TREATMENT ON HIV-1 p24 PRODUCTION IN INFECTED RESTING HUMAN LYMPHOCYTES) virus control DTFANHSA lOμM DTFANHSA lOOμM DTFANHSA loooμM FIGURE: 6 Figure 7 (a, b, c) each graphically depicts a study of the antiviral activity of DTFANHSA in combination with AZT on non-activated human PBMC infected with the HIV virus. (EFFECT OF DRUG TREATMENT ON HIV-1 p24 PRODUCTION IN INFECTED RESTING HUMAN LYMPHOCYTES) 10 μM + AZT 4μM lOμM FIGURE: 7a - 12 - M + ddl lOμM M FIGURE: 4c Figure 5 (a, b, c) each graphically depicts a study of the antiviral activity of DANHSA in combination with 3TC on non-activated human PBMC infected with the HIV virus. (EFFECT OF DRUG TREATMENT ON HIV-1 p24 PRODUCTION IN INFECTED RESTING HUMAN LYMPHOCYTES) virus control 3TC 5μM DANHSA lOμM + 3TC 5μM DANHSA lOμM FIGURE: 5a M + 3TC 5μM M FIGURE: 5b lOOOμM + ddC 0.2μM lOOOμM FIGURE: 8c Figure 9 (a, b, c) each graphically depicts a study of the antiviral activity of DTFANHSA in combination with ddl on non-activated human PBMC infected with the HIV virus. (EFFECT OF DRUG TREATMENT ON HIV-1 p24 PRODUCTION IN INFECTED RESTING HUMAN LYMPHOCYTES) " O virus control -D ddJ lOμM DTFANHSA lOμM + ddl lOμM DTFANHSA lOμM FIGURE: 9a lOOμM + ddl lOμM lOOμM FIGURE: 9b -14- l OOμM + AZT 4μM lOOμM FIGURE: 7b lOOOμM • *- AZT 4μM lOOOμM FIGURE: 7c Figure 8 (a, b, c) each graphically depicts a study of the antiviral activity of DTFANHSA in combination with ddC on non-activated human PBMC infected with the HIV virus. (EFFECT OF DRUG TREATMENT ON HIV-1 p24 PRODUCTION IN INFECTED RESTING HUMAN LYMPHOCYTES) O virus control π ddC 0.2μM DTFANHSA lOμM + ddC 0.2μM DTFANHSA lOμM FIGURE: 8a lOOμM + ddC 0,2μM lOOμM FIGURE: 8b lOOOμM + 3TC 5μM lOOOμM FIGURE: 10c DETAILED DESCRIPTION OF THE INVENTION The present invention provides a new family of compounds which are useful as anti-inflammatory agents and broncho-dilating agents. The compoundε are useful in a range of diseases which include arthritis and asthma. Additionally, these compounds are useful for anti-viral activity. This new family of compounds has the following formulas: I (linear form) II (cyclic form) wherein R 1 is an alkyl group of from 1 to 4 carbon atoms each optionally mono-, di-, or tri-substituted with halogen; each of R 2 , R 3 , R 4 is hydrogen or a straight or branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl radical containing 2 to 8 carbon atoms, an alkynyl radical containing 2 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a cycloalkenyl radical containing from 4 to 6 carbon atoms or a bicycloalkyl radical containing 7 to 11 carbon atoms, these radicals optionally being substituted by at least one substituent selected from halogen, hydroxyl, alkyloxy -16- lOOOμM + ddl lOμM lOOOμM FIGURE: 9c Figure 10 (a, b, c) each graphically depicts a study of the antiviral activity of DTFANHSA in combination with 3TC on non-activated human PBMC infected with the HIV virus. (EFFECT OF DRUG TREATMENT ON HIV-1 p24 PRODUCTION IN INFECTED RESTING HUMAN LYMPHOCYTES) virus control -D 3TC 5μM DTFANHSA lOμM + 3TC 5μM DTFANHSA lOμM FIGURE: 10a 100 μM + 3TC 5μM lOOμM FIGURE: 10b One general synthesis of these compounds is as follows O I ( linear form) II (cyclic form) -18- containing 1 to 4 carbon atoms, dialkyl amino, in which each alkyl contains 1 to 4 carbon atoms, phenyl alkyl in which the alkyl contains 1 to 4 carbon atoms, cyclo alkyl containing 3 to 6 carbon atoms, optionally substituted phenyl, cyano, carboxyl, or alkyloxy carbonyl in which the alkyl contains 1 to 4 carbon atoms; and n is an integer from 0 to 6. Compounds wherein R 1 is an alkyl group of from 1 to 4 carbons each optionally mono-, di-, or tri- substituted with halogen; R 2 , R 3 , and R 4 are each hydrogen and n = 1 to 4 are more preferred. Compounds wherein R 1 is CH 3 or CF 3 ; R 2 , R 3 , and R 4 are each hydrogen and n = 1 are most preferred. The present invention further provides for compositions comprising these compounds including pharmaceutical compositions which optionally contain a pharmaceutically acceptable carrier, excipient, vehicle or combination thereof. Further information regarding the synthesis is provided by Greenstein, J.P., initz, M. , Chemistry of the Amino Acids. John Wiley, New York, 1961, pp.927 and pp. 2065 and D. Stanley Tarbell, Yutaka Yama oto, and Barry M. Pope, Proc. Nat. Acad. Sci. USA. Vol. 69, No 3, 1972, pp.730-732. Merck Index 10, 8741, 8744, 8745, (1983), Warren, Briggs, Ber, 64, 29, (1931), M. Bodansky, A. Bodansky, The Practice of Peptide Synthesis. 125, (1984) and A.I. Vogel, Text-Book of Practical Organic Chemistry. 371, 375-377 and 840, (3rd. edition, 1957). All of these references are incorporated herein, in their entirety, by reference. Specifically, for example, D-acetamido-N-hydroxy succinamic acid and D-acetamido-N-hydroxy succinimide are obtained from D-aspartic acid or from D-asparagine according to the following sequence of reactions: -20- If n=0, the initial substrate of the reaction is D-serine. OOi 2 Oi STEP 1: SYNTHESIS OF D-ASPARTIC ACID β-ETHYL ESTER: D-aspartic acid 3-ethyl ester 13.31 g of D-aspartic acid (0.1 mole) are dissolved in 135 ml of absolute ethanol containing 8.7 g of dry hydrogen chloride. The reaction mixture is stirred for about 2 hr. The solution is diluted by addition of 250 ml of absolute ethanol. Triethylamine is then added dropwise until the solution becomes alkaline. After standing for 16 hr at +4°C, the obtained crystals are filtered, washed successively with cold absolute ethanol and ether, then dried. The reaction yields 11.5 g of D- aspartic acid 0-ethyl ester (71%) . NMR 13 C in D 2 0 (75.47 MHz) : d 14.3 ppm (CH 3 ) 35.04 ppm (CH 2 ) ; 50.2 ppm (CH) ; 63.7 (CH 2 -0) ; 171.7 ppm (C=o ester); 172.3 ppm (C=0-acid) . STEP 2: SYNTHESIS OF D-ASPARTIC ACID 0-HYDROXAMATE: D-aspartic acid β-hydroxamate -22- A. SYNTHESIS AND CHARACTERIZATION OF D-ACETAMIDO- N-HYDROXY SUCCINAMIC ACID (DANHSA) AND D-ACETAMIDO-N- HYDROXY SUCCINIMIDE D -α-acβt D-α-acetamido-N-hydroxy succinimide STEP 3: SYNTHESIS OF D-ACETAMIDO-N-HYDROXY SUCCINAMIC ACID AND D-ACETAMIDO-N-HYDROXY SUCCINIMIDE (Ac). O NaOH Cation exchange resin OH The cristals are triturated and washed with absolute ethanol α -ace mido-N-hyd xy s-tc namic ΛCΛC\ « -acelamido-N 1-hydroxy succinimide -24- 0.1 mole of D-aspartic acid β-ethyl ester is dissolved in 200 ml of methanol, 0.2 mole of hydroxylamine hydrochloride is then added and the mixture is stirred until complete dissolution occurs. 0.4 mole of triethylamine is added and stirring is continued at room temperature for about 48 hr. The precipitate formed is collected on a filter. Thiε crude product is recrystallized by dissolution in water, then diluted in absolute ethanol. This solution is kept at +4°C for 12 hr. The crystals are filtered, washed with absolute ethanol and air-dried. This reaction yields 50 to 70% of D- aspartic acid β-hydroxamate. Elemental analyses: calculated for C 2 H 8 N 2 0 4 (148.1): C = 32.41; H = 5.40; N = 18.90; O = 43.21. Found: C = 32.38; H = 5.31; N = 18.89; O = 43.26. RMN ! H in D 2 0 (300.13 MHz): (d) 2.7 ppm (dd, IH, j = 7.5, 16 Hz); 2.8 ppm (dd, IH, j = 4.5, 16 Hz); 4 ppm (dd, IH, j = 4.5, 7.5 Hz) ; 4.8 ppm (s, HOD). NMR 13 C in D 2 0 (75.47 MHZ) : d 32.8 ppm (CH 2 ) ; 51.7 ppm (CH) ; 169.0 ppm (C=0 hydroxamate) ; 173.4 ppm (C=0- acid) . RMN λ U in DMSO-D6 (300.13 MHz): d 12.6 ppm (s, IH aacciid));; 1100..44 ppppppmmm (((sss,,, IIHH NNHH)I ;; 8 a..8 a ppppmm ((ss,, IIHH NNOOHH)) ;; 88..11 ppppmm (d, IH NHI. 4.5 ppm (dd, IH CHJ., 2.4 et 2.3 ppm (2 dd, 2H C C s-LHH± 2 2,))';; i 11 J -.. m 88" pp fpfpmm"' ((Vss * -»,,» 33 J HH" CC-UHH3 3 „))' . • NMR 13 C in D 2 0 + 1 drop NaOD (75.47 MHz) : d 22.5 ppm (CH 3 ) ; 36.1 ppm (CH 2 ) ; 53.05 ppm (CH) ; 164.7 ppm (C=0 acetyl=; 174.1 ppm (C=0 hydroxamate) ; 178.6 ppm (C=0- acid) . FOR D-ACETAMIDO-N-HYDROXY SUCCINIMIDE: Elemental analyses: Calculated for C 6 H 8 N 2 0 4 (172,1) : C=41,83; H=4,65; N=16,27; 0=37,20. Found: C=41,55; H=4,75; N=16,55; 0=37,42. NMR 13 C in D 2 0 ( 75 , 47 MHz ) : δ 21 , 9 ppm ( CH 3 ) ; 33 , 2 ppm (CH 2 ) ; 47 , 3 ppm (CH) ; 174 , 5 ppm ( C=0 acetyl ) ; 173 , 9 and 175 ppm ( C=0) . RMN- in DMSO-D6 (300,13 MHz): δ 10,7 ppm (s, IH NOH); 8,5 ppm (d, IH NH) . 4,3 ppm (dd, IH CH) ; 2,9 et 2,4 ppm (2dd, 2H CH 2 ) ; 1,8 ppm (s, 3H CH 3 ) . The colorimetric determination of hydroxamic function: The hydroxamic function of DANHSA was observed by complex with the ferric ion, on a Beckman DU - 70 spectrophotometer. The iron complexes of hydroxamic acid are typically red - violet showing maximal absorption in the following wave range: 500-550 nm. Thin-layer Chromatography (TLC) : TLC was performed on Merck Kieselgel 60 F2 5 4 (0.2 mm layer thickness) in ethanol - water 8 : 2 (v/v) DANHSA gave a single spot, which was visualized by spraying with aqueous 2% Ferric chloride. -26- 29.6 g of D-Aspartic acid -hydroxamate are dissolved in 200 ml of cold 1 N NaOH. The solution is stirred in an ice-water bath. 40 ml of 1 N NaOH are added followed by 4.08 g of acetic anhydride. At this stage the pH of the solution should be alkaline; if not a small volume of 1 N NaOH should be added to obtain an alkaline pH. This process (addition of NaOH and acetic anhydride) is repeated four more times. At each step, the pH of the solution should be evaluated for adjustment as previously described. Stirring of solution is maintained at room temperature for 16hr-18hr. The reaction mixture is then applied to a cation exchange resin Dowex 50 W x 8 column. The elution is performed with water and the effluent obtained is evaporated in vacuo to dryness. The separation of the linear form ( -acetamido-N-hydroxy-succinamic acid) from the cyclic form (α-acetamido-N-hydroxy-succinimide) is achieved by triturating the crystals, washing with absolute ethanol, filtering and drying. This reaction yields 22 to 25 g of DANHSA. EVIDENCE OF CHEMICAL STRUCTURE FOR D-ACETAMIDO-N-HYDROXY SUCCINAMIC ACID: Elemental analyses: Calculated for C 6 H 10 N 2 0 5 (190.1): C = 37.87; H = 5.26; N = 14.72; O = 42.08. Found: C = 37.84; H = 5.19; N = 14.5; O = 42.25. Nuclear Magnetic resonance (NMR) : NMR spectra were recorded on a Bruker AM spectrometer in D 2 0 or DMSO-D 6 at 300.13 MHz and 75.47 MHz with tetramethylsilane (TMS) as external standard. Chemical shifts (d) are reported in ppm (parts per million) relative to TMS. RMN -H in D 2 0 (300.13 MHz): (d) 1.8 ppm (s 3H) ; 2.6 ppm (dd, IH, j = 7.5, 15 Hz) ; 2.7 ppm (dd, IH, j = 5.5, 15 Hz); 4.7 ppm (dd, IH, j = 5.5, 7.5 Hz); 4.8 ppm (s, HOD) . Elemental analyses: Calculated for C 6 H 7 N 2 0 5 F 3 1/2 H 2 0 (253.1): C = 28.44; H = 3.16; N = 11.06; F = 23.35. Found: C = 28.38; H = 3.18; N = 10.68; F = 22.45. Nuclear Magnetic resonance (NMR) : NMR 13 C in D 2 0 (75.47 MHz): d 32.4 ppm (CH 2 ); 46.8 ppm (CH) ; . 121.5; 117.7; 113.9 and 110.2 ppm (q, CF 3 j = 3.5 ppm) 160.3; 159.8; 159.3 and 158.8 ppm (q, C=0 j = 0.5 ppm TFA); 172.7 ppm (C=0 hydroxamate) ; 173.1 ppm (C=0- acid) . This new family of compounds either alone or in combination with at least one reverse transcriptase (RT) inhibitor, is useful for preventing, inhibiting or eliminating the spread of viruses and, in particular, for the treatment of a cell population in the presence of a retrovirus. Additionally, the invention encompasses pharmaceutical compositions intended, in particular, for the treatment and prevention of retroviral infections, especially those linked to HIV and AIDS wherein the compositions contain an additive or synergistic combination of at least any one of the new family of compounds including D-acetamido-N-hydroxy succinamic acid (DANHSA) ; D-acetamido-N-hydroxy succinimide; D- trifluoroacetamido-N-hydroxy succinamic acid (DTFANHSA) ; D-trifluoroacetamido-N-hydroxy succinimide; and salts thereof and at least one reverse transcriptase inhibitor; in particular an additive or synergistic combination of a dideoxynucleoside or more than one dideoxynucleoside and DANHSA or DTFANHSA; most preferably an additive or synergistic combination of any one of AZT, ddC, ddl or 3TC and DANHSA or DTFANHSA as active principle, in a pharmaceutically acceptable vehicle, or co-administered. The compositions of the present invention can also contain inert or pharmacodynamically active additives, carriers and/or excipients. -28- B. SYNTHESIS AND CHARACTERIZATION OF D- TRIFLUOROACETAMIDO-N-HYDROXY SUCCINAMIC ACID (DTFANHSA) AND D-TRIFLUOROACETAMIDO-N-HYDROXY SUCCINIMIDE D-trifluoroacetamido-N-hydroxy succinamic acid 0.1 mole of D-aspartic acid β-hydroxamate is dissolved in 60 ml of anhydrous trifluoroacetic acid. 0.14 mole of trifluoroacetic anhydride is added dropwise over a period of 1 1/2 to 2 hr. with stirring. After 4 hr, the excess of anhydride and trifluoroacetic acid is distiled under reduced pressure at 30 - 40°C. The residue is dissolved in water and filtered to cation exchange resin Dowex 50 W x 8 column. The elution is performed with water and the effluent obtained is evaporated in vacuo to dryness. The separation of the linear form (α-trifluoro- acetamido-N-hydroxy succinamic acid) from the cyclic form (α-trifluoroacetamido-N-hydroxy succinimide) is achieved by triturating the crystals, recrystallizing with ether, filtering and drying. This reaction yields 60% of DTFANHSA. The actual dosage administered will be determined by physical and physiological factors such as age, body weight, severity of condition, and/or clinical history of the patient. With these considerations in mind, the dosage of the compositions comprising the compounds of the present invention and those comprising an additive or synergistic combination for a particular subject can be readily determined by the physician. It might be noted that in extreme cases a dosage approaching the toxic level may be the acceptable treatment protocol. Compositions of the present invention comprising any one of the herein disclosed new family of compounds, such as for example, DANHSA or DTFANHSA, may contain these compounds in a concentration range of from about 0.5 μM to about 20,000 μM; preferably from about 1 μM to about 10,000 μM; more preferably from about 5 μM to about 5,000 μM; and most preferably from about 10 μM to about 1,000 μM. Other compositions may contain these compounds, having the same ranges, in combination with at least one inhibitor of reverse transcriptase or at least one dideoxynucleoside such as, for example ddl, at concentrations which are generally known and used in the art, or preferably from about 0.01 μM to about 200 μM; more preferably from about 0.1 μM to about 100 μM; most preferably from about 0.2 μM to about 10 μM. For example, in the treatment of HIV-infected and AIDS patients, compositions can be administered in dosage ranges such as to provide plasma concentrations in the range of from about 0.5 μM to about 20,000 μM; preferably from about 1 μM to about 10,000 μM; more preferably from about 5 μM to about 5,000 μM; and most preferably from about 10 μM to about 1,000 μM for the compounds of the present invention and for the reverse transcriptase inhibitor, a range which is generally known and used in the art, or preferably from about 0.01 μM to about 200 μM; -30- The pharmaceutical compositions of the invention can take the form of a lyophilized powder of the active substance, to be dissolved immediately before use in a physiological solution for the purpose of injection. The medicament can then be administered parenterally, for example intravenously, intraperitoneally, in the cerebrospinal fluid, and the like. For injection, the active principle is dissolved in a physiological solution until the desired concentration for administration is obtained. The pharmaceutical compositions according to the invention can also take a form which is suitable for oral administration. For example, suitable forms are tablets, hard gelatin capsules, dragees, powders and granules. The formation of such oral forms is well-known to those skilled in the art. Any of the known formulations are useful in preparing the instant oral pharmaceutical compositions. As regards the dosage of the medicament according to the invention, it will be clear to the artisan that the doses to be administered are variable according to the treatment period, and frequency of administration, the host and the nature and severity of the disease. The compositions of the present invention are administered in substantially non-toxic dosage concentrations sufficient to insure the release of a sufficient dosage unit of at least one compound of the new family of compounds herein disclosed for those compositions comprising same, into the patient to provide the desired inhibition of the spread of the retrovirus. For the compositions comprising a synergistic combination, these are also administered in substantially non-toxic dosage concentrations sufficient to insure the release of a sufficient dosage unit of the synergistic combination into the patient to provide the desired inhibition of the spread of the retrovirus. phytohemagglutinin (PHA) and interleukin-2 (IL-2) . TABLE 1 is a study of the anti-viral activity of DANHSA, AZT, ddC, ddl and 3TC alone and of DANHSA in combination with AZT, ddC, ddl and 3TC in non-activated human peripheral blood mononuclear cells (PBMC) infected with HIV as measured by p24 gag protein expressed in pg/ml. TABLE 2 is a study of the anti-viral activity of DTFANHSA, AZT, ddC, ddl and 3TC alone and of DTFANHSA in combination with AZT, ddC, ddl and 3TC in non-activated human peripheral blood mononuclear cells (PBMC) infected with HIV as measured by p24 gag protein expressed in pg/ml. Example 1 The anti-viral activity of DANHSA alone and in combination with RT inhibitors on non-activated resting human lymphocytes infected with HIV (see Table 1 and Figures 1 to 5) . PBMC were incubated with the viral strain HIV-1 Lai for two hours at 37°C with a multiplicity of infection of IO 4 TCID 50 per IO 6 cells. Unbound virus was then eliminated by two successive washes with culture medium and the cells were seeded at a density of 10 6 cells/ml in the presence of various drug concentrations. On day 7, supernatant were collected for p24 assay and cells were washed 3 times to remove traces of drug. Cells were then submitted to PHA activation by culture in fresh medium containing PHA (Murex lμ/ml) and recombinant IL-2 (Roussel 10 U/ml) . After 48 hrs of incubation, cells were washed to remove PHA and resuspended in fresh medium containing IL-2. These cultures were maintained for 3 weeks (days 9 to 28): on days 14, 21 and 28, half of the medium was taken and replaced either by fresh medium containing IL-2 (days 21 and 28) or by PHA-activated PBL from blood of healthy donors in RPMI medium 1640 supplemented with IL-2 -32- more preferably from about 0.1 μM to about 100 μM; most preferably from about 0.2 μM to about 10 μM. The present invention also covers the use of an RT inhibitor and any one of the new family of compounds including D-acetamido-N-hydroxy succinamic acid (DANHSA) ; D-acetamido-N-hydroxy succinimide; D-trifluoroacetamido-N- hydroxy succinamic acid (DTFANHSA) ; D-trifluoroacetamido- N-hydroxy succinimide; and salts thereof in combination with other medicinal compositions intended for the treatment of retroviral infections. Immunostimulants and immunomodulators such as for example cytokines, including IL-2, IL-12 and interferon molecules can be used in combination with the present invention. A preferred range for in vitro administration of the compositions of the present invention is from about 0.5 μM to about 20,000 μM; preferably from about 1 μM to about 10,000 μM; more preferably from about 5 μM to about 5,000 μM; and most preferably from about 10 μM to about 1,000 μM for the compounds of the present invention. For the reverse transcriptase inhibitor, a preferred range for in vitro administration is the range which is generally known and used in the art, or preferably from about 0.01 μM to about 200 μM; more preferably from about 0.1 μM to about 100 μM; and most preferably from about 0.2 μM to about 10 μM. EXAMPLES The following examples of specific embodiments of the present invention are offered for illustrative purposes only and are not limiting with respect to the scope of the disclosure or claim coverage. Testing of the mixture of DANHSA or DTFANHSA and any one of ddl, AZT, ddC or 3TC on the production of HIV was conducted on human peripheral blood mononuclear cells (PBMC) infected with HIV without prior activation/proliferation of these cells by The combination of 3TC and DANHSA which was also studied (see Figures 5a, 5b, 5c) inhibits viral production as from day 7 at the three concentrations of DANHSA in combination with 5 μM 3TC and synergistically inhibits viral production resulting in the complete elimination of HIV as from day 14 with DANHSA 100 μM and 1000 μM in combination with 5 μM 3TC. The new compound DANHSA has been shown to have no cytotoxic effect on a cell population even at very high concentrations as measured by its inhibitory effect on the enzyme ribonucleotide reductase. The inhibition of ribonucleotide reductase was measured by analyzing the concentration of the tyrosine radical. Experiments were conducted using a murine leukemia cell line L1210, transfected for hyperexpression of the R2 sub-unit which has the free radical. The cells which had been treated for 4 to 5 hours with DANHSA were analyzed by electronic paramagnetic resonance (EPR) . Under these conditions, a concentration of 4 mM DANHSA was shown to have no inhibitory effect. Example 2 The anti-viral activity of DTFANHSA alone and in combination with RT inhibitors on non-activated resting human lymphocytes infected with HIV (see Table 2 and Figures 6 to 10) . PBMC were incubated with the viral strain HIV-1 Lai for two hours at 37°C with a multiplicity of infection of IO 4 TCID 50 per 10 6 cells. Unbound virus was then eliminated by two successive washes with culture medium and the cells were seeded at a density of IO 6 cells/ml in the presence of various drug concentrations. On day 7, supernatant were collected for p2 assay and cells were washed 3 times to remove traces of drug. Cells were then submitted to PHA activation by culture in fresh medium containing PHA (Murex lμ/ml) and recombinant IL-2 (Roussel -34- on day 14 (4xl0 5 cells/ml) . Supernatant were kept for HIV p24 gag protein ELISA assay (DuPont) . Three concentrations of DANHSA were studied: 10, 100 and 1000 μM, and resulted in anti-HIV activity as measured by inhibition of viral production compared to infected non-treated control (see Figure 1) . On day 7, 10 μM DANHSA resulted in 98 % inhibition, 100 μM in 98.2 % inhibition, and 1000 μM in 98.2 % inhibition. On day 14, 10 μM resulted in 96.5 %, 100 μM in 88.2 %, and 1000 μM in 96.7 % inhibition respectively. A lesser inhibition is observed on day 21, and persists through day 28 with 10 μM resulting in 34.6 %, 100 μM in 60 % and 1000 μM in 60.8 % inhibition respectively. 100 μM and 1000 μM DANHSA alone resulted in greater inhibition of viral production than 4 μM AZT alone (see Figures 2b, 2c) . The combination of AZT and DANHSA was also studied (see Figures 2a, 2b, 2c). At day 7, the 98.2 % inhibition of viral production observed with the combination of 1000 μM DANHSA and 4 μM AZT is equivalent to that observed with 1000 μM DANHSA alone compared to infected non-treated control. However, surprisingly, at day 14 the combination of 1000 μM DANHSA and 4 μM AZT resulted in a synergistic inhibitory effect on viral production with 99.997 % inhibition. The combination of ddC and DANHSA which was also studied (see Figures 3a, 3b, 3c) synergistically inhibits viral production resulting in the complete elimination of HIV as from day 14 with 1000 μM DANHSA and 0.2 μM ddC. The combination of ddl and DANHSA which was also studied (see Figures 4a, 4b, 4c) synergistically inhibits viral production resulting in the complete elimination of HIV as from day 14 for the three concentrations of DANHSA in combination with 10 μM ddl. production as from day 7 at the three concentrations of DTFANHSA in combination with 5 μM 3TC and synergistically inhibits viral production resulting in the complete elimination of HIV as from day 14 with DTFANHSA 100 μM and 1000 μM in combination with 5 μM 3TC. Example 3 An example of the potential use in treating asthma is presented as follows. A patient suffering from difficulty in breathing was administered 5 ml. of an aqueous solution containing 25 mg. of DANHSA by oral route and within some minutes experienced the effects of broncho-dilation, making his breathing considerably easier. -36- 10 U/ml) . After 48 hrs of incubation, cells were washed to remove PHA and resuspended in fresh medium containing IL-2. These cultures were maintained for 3 weeks (days 9 to 28) : on days 14, 21 and 28, half of the medium was taken and replaced either by fresh medium containing IL-2 (days 21 and 28) or by PHA-activated PBL from blood of healthy donors in RPMI medium 1640 supplemented with IL-2 on day 14 (4x10 s cells/ml) . Supernatant were kept for HIV p24 gag protein ELISA assay (DuPont) . The anti-viral effect of three concentrations of DTFANHSA was studied: 10, 100 and 1000 μM alone and in combination with each of four RT inhibitors as measured by inhibition of viral production compared to infected non- treated controls (see Figures 6 to 10) . The combination of the three concentrations of DTFANHSA with 4 μM AZT was studied (see Figures 7a, 7b, 7c) and resulted on day 7 in an inhibitory effect on viral production with 96.6 to 96.9 % inhibition compared to infected non-treated control, whereas AZT alone resulted in 90.7 % inhibition. The combination of ddC and DTFANHSA which was also studied (see Figures 8a, 8b, 8c) inhibits viral production at day 7 at the three concentrations of DTFANHSA in combination with 0.2 μM ddC and synergistically inhibits viral production resulting in the complete elimination of HIV as from day 14 with 1000 μM DTFANHSA in combination with 0.2 μM ddC. The combination of ddl and DTFANHSA which was also studied (see Figures 9a, 9b, 9c) inhibits viral production at day 7 at the three concentrations of DTFANHSA in combination with 10 μM ddl and synergistically inhibits viral production resulting in the complete elimination of HIV at day 28 for the three concentrations of DTFANHSA in combination with 10 μM ddl. The combination of 3TC and DTFANHSA which was also studied (see Figures 10a, 10b, 10c) inhibits viral TABLE 2. Anti-viral activity of DTFΛMHSA, ΛZT, (\c C, ddj nnd 3TC alone and in various combinations in non-nctivntcd human peripheral blood mononuclear cells (PBMC) infected with HTV as measured by p24 gag protein expressed in pg/mj. What is claimed is : 1. A compound having the following linear or cyclic formulas: I (linear form) II (cyclic form) wherein R 1 is an alkyl group of from 1 to 4 carbon atoms optionally mono-, -di, or tri-substituted with halogen; each of R 2 , R 3 , and R 4 is hydrogen, or a straight or branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl radical containing 2 to 8 carbon atoms, an alkynyl radical containing 2 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a cycloalkenyl radical containing from 4 to 6 carbon atoms or a bicycloalkyl radical containing 7 to ll carbon atoms, these radicals optionally being substituted by at least one substituent selected from halogen, hydroxyl, alkyloxy containing 1 to 4 carbon atoms, dialkyl amino, in which each alkyl contains 1 to 4 carbon atoms, phenyl alkyl in which the alkyl contains 1 to 4 carbon atoms, cyclo alkyl containing 3 to 6 carbon atoms, optionally substituted phenyl, cyano, carboxyl, or alkyloxy carbonyl in which the alkyl contains 1 to 4 carbon atoms; n is an integer from 0 to 6; and salts thereof. -40- The invention has been described with reference to specific and preferred embodiments. It will be recognized by those skilled in the art that numerous changes and substitutions may be made without departing from the spirit and scope of the invention.

Claims: claims 3 to 6, characterized in that the concentration of the reverse transcriptase inhibitor is selected from the group consisting of the following concentration ranges : - from about 0,01 μM to about 200 μM ; - from about 0,1 μM to about 100 μM ; - from about 0,2 μM to about 10 μM . 9/ A medicament comprising a compound according to claim 1 or 2 , or a composition according to anyone of claims 3 to 8. 10/ A medicament according to claim 9, characterized in that its composition is further selected so as to provide a plasma concentration selected from the group consisting of the following concentration ranges : - from about 0,5 μM to about 20000 μM ; - from about 1 μM to about 10000 μM ; - from about 5 μM to about 5000 μM ; - from about 10 μM to about 1000 μM. 11/ A medicament according to claim 9 or 10, characterized in that it further comprises a pharmaceutically acceptable carrier, or excipient, or vehicle, or combination thereof. 12/ A medicament according to anyone of claims 9 to 11, for use in inhibiting the production or spread of a virus, or for limiting the spread of a virus, or for blocking the production of a virus. 13/ A medicament according to claim 12, characterized in that said virus is selected from the group consisting of HSV Type l, HSV Type 2, HBV, HCV, CMV and Epstein Barr. 14/ A medicament according to claim 12, -42- 2. A compound according to claim 1, characterized in that it is selected from the group consisting of D-acetamido-N-hydroxy succinamic acid (DANHSA) , D-acetamido-N-hydroxy succinimide, D-trifluoro acetamido-N-hydroxy succinamic acid (DTFANHSA) , D-trifluoroacetamido-N-hydroxy succinimide ; and salts thereof. 3/ A composition comprising a compound according to claim 1 and 2, and one reverse transcriptase inhibitor. 4/ A composition according to claim 3, characterized in that said reverse transcriptase inhibitor is a dideoxynucleoside. 5/ A composition according to claim 4, characterized in that the dideoxynucleoside is selected from the group consisting of AZT, ddC, ddA, ddG, ddl, ddT, 3TC and d4T. 6/ A composition according to claim 5, characterized in that the dideoxynucleoside is ddl, AZT, ddC or 3TC. 7/ A composition according to anyone of claims 3 to 6, characterized in that the concentration of the compound according to claim 1 or 2 is selected from the group consisting of the following concentration ranges : - from about 0,5 μM to about 20000 μM ; - from about 1 μM to about 10000 μM ; - from about 5 μM to about 5000 μM ; - from about 10 μM to about 1000 μM . 8/ A composition according to anyone of the 22/ Use according to claim 19 for the preparation of a medicament for the treatment of HIV infected and AIDS patients. -44- characterized in that said virus is a retrovirus. 15/ A medicament according to claim 14, characterized in that said retrovirus is selected from the group consisting of HIV-l, HIV-2 , HTLV-1, HTLV-2, and SIV. 16/ A medicament according to anyone of claims 9 to 11, for the treatment of HIV infected and AIDS patients. 17/ A medicament according to anyone of claims 14 to 16, characterized in that it further comprises another medicinal composition or compound intended for treatment of retroviral infections, selected from the group consisting of immunostimulants, immunomodulators, cytokines, IL-2 , IL-12, and interferon molecules. 18/ Use of a compound according to claim 1 or 2 , or a composition according to anyone of claims 3 to 6 acting as a synergistic combination, for the preparation of a medicament. 19/ Use according to claim 18 for the preparation of a medicament for use in inhibiting the production or spread of a virus, or for limiting the spread of a virus, or for blocking the production of a virus. 20/ Use according to claim 19, characterized in that said virus is a retrovirus. 21/ Use according to claim 20, characterized in that said retrovirus is selected from the group consisting Of HIV-l, HIV-2, HTLV-1, HTLV-2, SIV, HSV, HBV or HCV. 2/ A compound having the following linear or cyclic formulas: I (linear form) II (cyclic form) wherein R 1 is an alkyl group of from 1 to 4 carbon atoms optionally mono-, -di, or tri-substituted with halogen, with the exclusion of a methyl group where the compound is in linear form (I) , each of R 2 and R 3 is hydrogen, and n = 1 or 2, or where the compound is in cyclic form, each of R 2 , R 3 and R 4 is hydrogen, and n = 1; each of R 2 , R 3 , and R 4 is hydrogen, or a straight or branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl radical containing 2 to 8 carbon atoms, an alkynyl radical containing 2 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a cycloalkenyl radical containing from 4 to 6 carbon atoms or a bicycloalkyl radical containing 7 to 11 carbon atoms, these radicals optionally being substituted by at least one substituent selected from halogen, hydroxyl, alkyloxy containing 1 to 4 carbon •atoms, dialkyl amino, in which each alkyl contains 1 to 4 carbon atoms, phenyl alkyl in which the alkyl contains 1 to 4 carbon atoms, cyclo alkyl containing 3 to 6 carbon atoms, optionally substituted phenyl, cyano, carboxyl, or alkyloxy carbonyl in which the alkyl contains 1 to 4 carbon atoms; n is an integer from 0 to 6; and salts thereof. -46- AMENDED CLAIMS [received by the International Bureau on 18 February 1997 (18.02.97) ; original claims 1 -22 replaced by amended claims 1 -23 (6 pages ) ] 1/ A D-compound having the following linear or cyclic formulas : I (linear form) II (cyclic form) wherein R 1 is an alkyl group of from 1 to 4 carbon atoms optionally mono-, -di, or tri-substituted with halogen; each of R 2 , R 3 , and R 4 is hydrogen, or a straight or branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl radical containing 2 to 8 carbon atoms, an alkynyl radical containing 2 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a cycloalkenyl radical containing from 4 to 6 carbon atoms or a bicycloalkyl radical containing 7 to 11 carbon atoms, these radicals optionally being substituted by at least one substituent selected from halogen, hydroxyl, alkyloxy containing 1 to 4 carbon atoms, dialkyl amino, in which each alkyl contains 1 to 4 carbon atoms, phenyl alkyl in which the alkyl contains 1 to 4 carbon atoms, cyclo alkyl containing 3 to 6 carbon atoms, optionally substituted phenyl, cyano, carboxyl, or alkyloxy carbonyl in which the alkyl contains 1 to 4 carbon atoms; n is an integer from 0 to 6; and salts thereof. 9/ A composition according to anyone of the claims 4 to 7, characterized in that the concentration of the reverse transcriptase inhibitor is selected from the group consisting of the following concentration ranges : - from about 0,01 μM to about 200 μM ; - from about 0,1 μM to about 100 μM ; - from about 0,2 μM to about 10 μM . 10/ A medicament comprising a compound according to anyone of claims 1 to 3, or a composition according to anyone of claims 4 to 9. 11/ A medicament according to claim 10, characterized in that its composition is further selected so as to provide a plasma concentration selected from the group consisting of the following concentration ranges : - from about 0,5 μM to about 20000 μM ; - from about 1 μM to about 10000 μM ; - from about 5 μM to about 5000 μM ; - from about 10 μM to about 1000 μM. 12/ A medicament according to claim 10 or 11, characterized in that it further comprises a pharmaceutically acceptable carrier, or excipient, or vehicle, or combination thereof. 13/ A medicament according to anyone of claims 10 to 12, for use in inhibiting the production or spread of a virus, or for limiting the spread of a virus, or for blocking the production of a virus. 14/ A medicament according to claim 13, characterized in that said virus is selected from the group consisting of HSV Type 1, HSV Type 2, HBV, HCV, CMV and Epstein Barr. -48- 3/ A compound according to claim 1, characterized in that it is selected from the group consisting of D-acetamido-N-hydroxy succinamic acid (DANHSA) , D-acetamido-N-hydroxy succinimide, D-trifluoro acetamido-N-hydroxy succinamic acid (DTFANHSA) , D-trifluoroacetamido-N-hydroxy succinimide ; and salts thereof. 4/ A composition comprising a compound according to anyone of claims l to 3, and one reverse transcriptase inhibitor. 5/ A composition according to claim 4, characterized in that said reverse transcriptase inhibitor is a dideoxynucleoside. 6/ A composition according to claim 5, characterized in that the dideoxynucleoside is selected from the group consisting of AZT, ddC, ddA, ddG, ddl, ddT, 3TC and d4T. 7/ A composition according to claim 6, characterized in that the dideoxynucleoside is ddl, AZT, ddC or 3TC. 8/ A composition according to anyone of claims 4 to 7, characterized in that the concentration of the compound according to anyone of claims 1 to 3 is selected from the group consisting of the following concentration ranges : - from about 0,5 μM to about 20000 μM ; - from about 1 μM to about 10000 μM ; - from about 5 μM to about 5000 μM ; - from about 10 μM to about 1000 μM . or HCV . 23/ Use according to claim 20 for the preparation of a medicament for the treatment of HIV infected and AIDS patients. -50- 15/ A medicament according to claim 13, characterized in that said virus is a retrovirus. 16/ A medicament according to claim 15, characterized in that said retrovirus is selected from the group consisting of HIV-l, HIV-2 , HTLV-1, HTLV-2, and SIV. 17/ A medicament according to anyone of claims 10 to 12, for the treatment of HIV infected and AIDS patients. 18/ A medicament according to anyone of claims 15 to 17, characterized in that it further comprises another medicinal composition or compound intended for treatment of retroviral infections, selected from the group consisting of immunostimulants, immunomodulators, cytokines, IL-2, IL-12, and interferon molecules. 19/ Use of a compound according to anyone of claims 1 to 3, or a composition according to anyone of claims 4 to 7 acting as a synergistic combination, for the preparation of a medicament. 20/ Use according to claim 19 for the preparation of a medicament for use in inhibiting the production or spread of a virus, or for limiting the spread of a virus, or for blocking the production of a virus. 21/ Use according to claim 20, characterized in that said virus is a retrovirus. 22/ Use according to claim 21, characterized in that said retrovirus is selected from the group consisting of HIV-l, HIV-2 , HTLV-1, HTLV-2 , SIV, HSV, HBV

Inventors: GRANGE JACQUES, HAMEDI-SANGSARI FARID, NUGIER FABIENNE, VALLET THIERRY, VILA JORGE, GRANGE, JACQUES, HAMEDI-SANGSARI, FARID, NUGIER, FABIENNE, VALLET, THIERRY, VILA, JORGE
Applicants: AGUETTANT LAB, COMPAGNIE DE DEVELOPPEMENT AGUETTANT
Application year: 1996
Main classification: C07C259
IPC codes: A61K31, A61P29, A61P31, C07C259, C07D207